Tempus AI in line for $200M from AstraZeneca cancer model deal - Fierce Biotech
... an AI model that can process and generate outputs from multiple data types. In return, Tempus is set to receive $200 million in data licensing and ...
Read the original at Fierce Biotech ↗
- Topics
- HealthcareCopyright & IP
- Tracked via
- “An AI Model that”